ABSTRACT

Objective: The aim of this work was to study the pharmacophore model of omega-3 derivatives with the PPAR-γ receptor using LigandScout 4.4.3 to investigate the important chemical interactions of complex structure.

Methods: The methods consisted of structure preparation of nine chemical compounds derived from omega-3 fatty acids, database preparation, creating 3D Pharmacophore modelling, validation pharmacophore, and screening test compounds.

Results: The result of the research showed that the omega-3 derivatives docosahexaenoic acid (DHA), when eicosapentaenoic acid (HPA), and docosapentaenoic acid (DPA) have the best pharmacophore fit values of 36.59, 36.56, and 36.56, respectively. According to the results of the pharmacophore study, the carbonyl and hydroxyl of the carboxylate functional groups become the active functional groups that exhibit hydrogen bonding interactions. While the alkyl chain (Ethyl and methyl groups) was the portion that can be modified to increase its activity.

Conclusion: Omega-3 derivatives could be used as a lead drug for the powerful PPAR-γ receptor in the prevention and treatment of obesity.

Keywords: 3D-Pharmacophore modelling, Omega-3 derivatives, PPAR-γ, and Obesity
Validation pharmacophore

The ten pharmacophore models that were obtained were tested one by one to determine which one was the best. In the screening column, each pharmacophore model is entered, as well as the database for active and decoy compounds. Then click the “screening perspective” to perform screening pharmacophores. The Receiver Operating Characteristic (ROC) curve was used to assess the validity of the pharmacophores [9].

Screening test compounds

The test compound database that was previously generated is loaded in the screening column. In the ligand-based section, the best pharmacophore model was then sent to the screening column for further processing to determine the best compound based on the highest pharmacophore fit score [9].

RESULTS

The ROC curve was used to assess the validity of the pharmacophore. The trade-off between sensitivity (or TPR) and specificity (1 – FPR) is depicted by the ROC curve. Classifiers with curves that are closer to the top-left corner perform better. The test becomes less accurate when the curve approaches the ROC space’s 45-degree diagonal [10]. From the study, we had founded that pharmacophore model 4 has best ROC curve value.

![Image of 2D molecular structure of omega-3 derivates](image)

**Fig. 1: The 2D molecular structure of omega-3 derivates**

| Compound          | Pharmacophore-fit score | Binding energy (kcal/mol) |
|-------------------|-------------------------|---------------------------|
| Docosahexaenoic   | 36.59                   | -11.31                    |
| Docosapentaenoic  | 36.56                   | -11.01                    |
| Eicosapentaenoic  | 36.56                   | -10.82                    |
| Hexadecatrienoic  | 35.45                   | -9.56                     |
| Heneicosapentaenoic | 35.28                  | -10.98                    |
| Stearidonic       | 35.27                   | -10.09                    |
| Alpha Linolenic   | 35.08                   | -10.07                    |
| Eicosatetraenoic  | 35.02                   | -10.50                    |
| Eicosatrienoic    | 34.46                   | -10.70                    |

![Image of 3D structure-based pharmacophore model](image)

**Fig. 2: The 3D structure-based pharmacophore model was validated using a Receiver Operating Characteristic (ROC) curve, with a set of 100 PPAR-γ active and 400 decoy compounds**

Table 1: LigandScout pharmacophore fit score of Omega-3 derivatives retrieved using the 3D-structure-based pharmacophore derived from propionic acid bound to the peroxisome Proliferator-activated receptor gamma

The nine compounds of Omega-3 derivatives were screened for pharmacophore similarity to the best pharmacophore model (model 4), which is a pharmacophore composed of compounds that have been shown to have activity targeting PPAR-γ receptors. The activity was evaluated based on the pharmacophore fit value. A higher fit score indicates a better fit to the model. From this study, docosahexaenoic (DHA), docosapentaenoic (DPA), and eicosapentaenoic (EPA) have the highest pharmacophore fit value.
In a molecular interaction study, the arrangement of functional groups that act as active sites of a structure was studied and assessed against their role in interacting with receptors. The angle and distance to the confirmation of the functional groups that make up a molecule have a significant effect on the ability to interact with receptors [11-13]. By comparing the results of pattern interaction between docosahexaenoic acid and propionic acid, we found that both have a similar amino acid residue on the carboxylic acid functional group, which can be seen on fig. 3A and 3B; these compounds interact with TYR473A and SER289A amino acid residue.

**DISCUSSION**

At the beginning with pharmacophore validation, the ROC curve values were derived based on the validation findings of the 10 best pharmacophore models (0.65, 0.61, 0.78, 0.66, 0.54, 0.75, 0.75, 0.66, and 0.62), where these results demonstrated that 3 out of 10 pharmacophores met the requirements. Models 4, 7, and 8 were validated [e0.7]. Model 4 was chosen because it had the greatest ROC curve value (AUC: 0.78), indicating that the pharmacophore model was able to properly distinguish active from decoy PPAR-γ molecules in accordance with Kirchmair’s methods [14]. The ROC curve value can be seen in fig. 2.

In addition, as a result of pharmacophore fit value, compounds that fit the pharmacophore model should likewise have PPAR-γ activity. Because not all of the model’s features could be matched, throughout the virtual screening process, two features could be excluded. In this instance, pharmacophore fit scores would be lower if features could not be matched. Interestingly, all of the derivatives had higher pharmacophore fit scores (34.46 to 36.59) than the parent compound, with docosahexaenoic (36.59) and docosapentaenoic (36.56) having the best pharmacophore fit scores with the lowest of binding energy (-11.31 and -11.01 kcal/mol, respectively), indicating that their chemical features aligned best with the features of the pharmacophore model [15]. A higher geometric alignment of the compound’s characteristics to the 3D-pharmacophore model is indicated by a higher fit score. Each compound’s binding energy is presented for comparison (table 1). The suitability of the pharmacophore features on the ligands makes it easy for these to interact, which is correlated with lower binding energy values. Binding energy value describes how spontaneous an interaction will occur. The lower the binding energy, the lower the activation energy, implying that it does not need a lot of energy to create the contact system between the ligand and the receptor, resulting in a spontaneous reaction. In addition, the best four compounds based on the fit-pharmacophore value have a correlation with the binding energy value, with the highest fit-pharmacophore value having the best binding energy.

Furthermore, pharmacophore Modelling and Molecular Interaction Propionic acid (the parent compound) was employed as a lead compound or a comparative for Omega-3 derivatives in this investigation. Propionic acid was chosen as the lead compound since it has been shown to interact with Peroxisome Proliferator-Activated Receptors in prior investigations. Furthermore, the N-methylene-substituted indole 5-propionic acid provides a suitable bio-isosteric replacement for the known tyrosine-based scaffold in PPAR-γ. The carboxylate and nitrogen groups in oxazole from Propionic Acid become acceptors of hydrogen bonding interactions, which interact with amino acids SER289A, TYR473A, and HOH1073A, as shown by pharmacophore modeling studies (fig. 3-4) [16].

This result is analogous to the hydrogen bonding interactions formed in Omega-3 derivative compounds (docosahexaenoic acid), where the carboxylic groups’ hydroxy (OH) and carbonyl (C=O) interactions function as donors and acceptors of hydrogen bonding interaction. And because of amino acids bound in TYR473A and SER289A are similar with the hydrogen bonding interactions that are present in propionic acid-PPAR-γ interaction and also same of functional group (Hydroxy carbonyl from carboxylic acid), this indicates that Docosahexaenoic Acid has the same mechanism of action [17]. Based on these results that the lead compound (Propionic Acid) has one sort of hydrogen bonding contact, namely the nitrogen atom in oxazole with the amino acid CH1073A, which Docosahexaenoic Acid does not, but by considering two types of amino acid residues in the hydrogen bonding interactions. As well as, docosahexaenoic acid can be considered to have the same action.

---

**Fig. 3A: 2D-Pharmacophore model of propionic acid (Parent Compound) as a lead compound with the peroxisome proliferator-activated receptor gamma (PPAR-γ); 3B: 2D-pharmacophore model of docosahexaenoic acid with the peroxisome proliferator-activated receptor gamma (PPAR-γ)**

**Fig. 4: 3D-Pharmacophore model of docosahexaenoic acid with the peroxisome proliferator-activated receptor gamma (PPAR-γ)**
as other identical amino acids due to have a comparable with hydrophobic interaction (LEU330A, MET338A, ILE341A, ILE281A, ILE362A, MET364A, PHE282A, LEU453A, and PHE363A). The fact that these two drugs have a comparable dominant interaction implies that they are positioned at the same active site. The carboxylate group is a pharmacophore structure that plays a key role in interacting with the PPAR-γ receptor, as seen in the two structures.

CONCLUSION

The carboxyl and hydroxyl of the carboxylate functional groups from docosahexaenoic acid become the active functional groups that exhibit hydrogen bonding interactions, according to the results of the pharmacophore study. The alkyl chain (the ethyl and methyl groups) in docosahexaenoic Acid is the part that can be modified to boost activity. The fact that docosahexaenoic acid type of interaction is identical that occurs in the carboxylate group, both on the parent compound and on docosahexaenoic Acid with the same amino acid residues on TYR473A and SER289A. It suggests that docosahexaenoic acid could be used as a potential drug for the powerful PPAR-γ receptor in the prevention and treatment of obesity.

ACKNOWLEDGMENT

This research was supported by Universitas Padjadjaran of Internal Grant through R&DPP 2021.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICTS OF INTERESTS

Declared none

REFERENCES

1. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance ofatherogenic dyslipidemia, in person with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4(2):113-9. doi: 10.1111/j.1559-4572.2008.00044.x, PMID 1964799.
2. Kolaki C, Liatsis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. doi: 10.1016/j.metabol.2018.10.011, PMID 30399375.
3. Morgan PJ, Young MD, Lloyd AB, Wang ML, Eather N, Miller A, Murtagh EM, Barnes AT, Pagoto SL. Involvement of fathers in pediatric obesity treatment and prevention trials: A systematic review. Pediatrics. 2017;139(2):1-18. doi: 10.1542/peds.2016-2635, PMID 28130430.
4. Calder PC. Very long-chain n-3 fatty acids and human health: fact, fiction and the future. Proc Nutr Soc. 2010;70(1):52-72. doi: 10.1017/S0032945611700395, PMID 20939280.
5. Senthil R, Sakthivel M, Usha S. Structure-based drug design of peroxisome proliferator-activated receptor gamma agonists: ferulic acid and derivatives. J Biomol Struct Dyn. 2021;39(4):1295-311. doi: 10.1080/07391102.2020.1740790, PMID 3215189.
6. Wang Y, Yao Y, Liu J, Wu L, Liu T, Cui J, Lee DY. Synthesis and biological activity of piperine derivatives as potential PPARγ agonists. Drug Des Devel Ther. 2020;14:2069-78. doi: 10.2147/DDDT.S238245, PMID 32546971.
7. Megawati G, Herawati DMD, Musfiroh I. Binding affinity of omega 3 fatty acid an agonist PPAR-γ GPR120 receptor for obesity using molecular docking and ADME prediction. Eur J Mol Clin Med. 2021;7(10):1868-95.
8. Deckerbaum LJ, Isser JM, Donaldson LF, LaLiberte SM, Clarke RH, Salem DN. Use of pulsed energy delivery to minimize tissue injury resulting from carbon dioxide laser irradiation of cardiovascular tissues. J Am Coll Cardiol. 1986;7(4):898-908. doi: 10.1016/s0735-1097(96)80355-2, PMID 3082956.
9. Seidel T, Bryant SD, Ibis G, Poli G. Langer. 3D pharmacophore modeling techniques in computer-aided molecular design using LigandScout. Tutor Chemoinform. 2017;281:279-309.
10. Zou KH, O’Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115(5):654-7. doi: 10.1161/circulationaha.107.665279, PMID 17283280.
11. Caporuscio F, Tafi A. Pharmacophore modelling: a forty-year-old approach and its modern synergies. Curr Med Chem. 2011;18(17):2543-53. doi: 10.2174/092986711795933669, PMID 21568993.
12. Choudhury C, Narahari Sastry G. Pharmacophore modelling and screening: concepts, recent developments and applications in rational drug design. Challenges and Advances in Computational Chemistry and Physics; 2019. p. 25-53. doi: 10.1007/978-93-030-0526-9_2.
13. Voet A, Zhang KY. Pharmacophore modelling as a virtual screening tool for the discovery of small-molecule protein-protein interaction inhibitors. Curr Pharm Des. 2012;18(30):4580-98. doi: 10.2174/138161212802651616, PMID 22650262.
14. Kirchmair J, Dietino S, Markt P, Schuster D, Spitzer GM, Liedl KR, Wolber G. How to optimize shape-based virtual screening: choosing the right query and including chemical information. J Chem Inf Model. 2009;49(3):678-92. doi: 10.1021/ci8004226, PMID 19434901.
15. Seidel T, Ibis G, Bendix F, Wolber G. Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Technol. 2010;7(4):e221-8. doi: 10.1016/j.dddtc.2010.11.004.
16. Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Marki HP, Meyer M, Mohr P. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists. Bioorg Med Chem Lett. 2006;16(15):4016-20. doi: 10.1016/j.bmcl.2006.05.007, PMID 16737814.
17. Chang S, Jiao X, Li CH, Gong XQ, Chen WZ, Wang CX. Amino acid network and its scoring application in protein-protein docking. Biophys Chem. 2008;134(3):111-8. doi: 10.1016/j.bpc.2007.12.005, PMID 18329160.